Product Description
A phosphorothioate oligonucleotide harboring nucleotide sequences complementary to tumor suppressor p53 mRNA. Cenersen hybridizes with p53 mRNA molecules, and induces Rnase H dependent hydrolysis of p53 transcripts in the double stranded section of the hybrids, thereby resulting in loss of p53 production. Loss of p53 activity leads to sensitization of cancer cells to other therapeutics. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cenersen)
Mechanisms of Action: p53 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eleos
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Acute Myeloid Leukemia
Phase 1: Anemia|Myelodysplastic Syndrome|Preleukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Other |
2020-07-31 |
|
| MDS ELP9001 | P1 |
Terminated |
Myelodysplastic Syndrome|Preleukemia|Anemia |
2015-09-30 |
22% |
| ELP1020 | P2 |
Withdrawn |
Acute Myeloid Leukemia |
2012-01-01 |
|
| 2008-002160-34 | P2 |
Terminated |
Acute Myeloid Leukemia |
2010-10-24 |